Literature DB >> 8568811

Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.

Y Qian1, A Vogt, S M Sebti, A D Hamilton.   

Abstract

Cysteine farnesylation of the ras oncogene product Ras is required for its transforming activity and is catalyzed by farnesyltransferase (FTase). The Ras carboxyl terminal tetrapeptide CAAX (C is cysteine, A is any aliphatic amino acid, X is methionine or serine) is the minimum sequence for FTase recognition. We report here the design, synthesis, and biological characterization of Ras CAAX non-peptide mimetics in which the cysteine is linked through a reduced pseudopeptide bond to 4-amino-3'-carboxybiphenyl. These non-peptide mimetics are potent inhibitors of FTase (IC50 = 40 nM for the most potent inhibitor) and are highly selective for FTase over GGTase I (geranylgeranyltransferase I). They are not substrates for farnesylation, do not have peptidic features, and have no hydrolyzable bonds. Structure-activity studies reveal the importance of the position of the carboxylic acid on the aryl ring as well as the reduction of the cysteine amide bond. Substitution at the 2-position of 4-amino-3'-carboxybiphenyl increases inhibitory potency, while the removal of the carboxylic acid results in a 10-fold loss of inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8568811     DOI: 10.1021/jm950414g

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Substrate specificity determinants in the farnesyltransferase beta-subunit.

Authors:  C E Trueblood; V L Boyartchuk; J Rine
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

2.  Conformational analysis of a farnesyltransferase peptide inhibitor, CVIM.

Authors:  L Carlacci
Journal:  J Comput Aided Mol Des       Date:  2000-05       Impact factor: 3.686

3.  Virtual lead identification of farnesyltransferase inhibitors based on ligand and structure-based pharmacophore techniques.

Authors:  Qosay A Al-Balas; Haneen A Amawi; Mohammad A Hassan; Amjad M Qandil; Ammar M Almaaytah; Nizar M Mhaidat
Journal:  Pharmaceuticals (Basel)       Date:  2013-05-27

4.  Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways.

Authors:  Hsin-Lin Cheng; Chiao-Wen Lin; Jia-Sin Yang; Ming-Ju Hsieh; Shun-Fa Yang; Ko-Hsiu Lu
Journal:  Oncotarget       Date:  2016-03-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.